Literature DB >> 7940433

Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study.

I Wahedna1, S Cooper, J Williams, I C Paterson, J R Britton, A E Tattersfield.   

Abstract

BACKGROUND: Pulmonary lymphangioleiomyomatosis is a rare progressive disease of unknown aetiology affecting premenopausal women. Since the oral contraceptive pill has been implicated in its pathogenesis, a case control study was carried out to determine whether women with the disease were more likely to have taken the oral contraceptive pill, and whether the disease was associated with other conditions related to sex hormones including pregnancy, parity, and fibroids.
METHODS: All chest physicians in the UK were asked for details of all live patients with pulmonary lymphangioleiomyomatosis; the patient's family doctor was then asked for four age and sex matched control subjects from their patient register. Details of lifetime use of the oral contraceptive pill, pregnancy, parity, history of fibroids, and smoking were obtained from cases and controls. Relative odds of exposure to potential risk factors were estimated by conditional logistic regression.
RESULTS: Medical details were obtained from all 23 cases of lymphangioleiomyomatosis identified; questionnaires were completed by 21 cases (one by proxy) and by 46 matched controls of mean (SD) age 43 (10) and 44 (11) years, respectively. The patients had a mean age of 34 (9) years at onset of symptoms and a median (range) time of 2 (0-29) years from onset of symptoms to diagnosis. Compared with control subjects, cases did not differ in the use of the oral contraceptive pill (odds ratio (OR) 0.39, 95% CI 0.09 to 1.68), diagnosis of fibroids (OR 3.12; 95% CI 0.52 to 18.7), age of menarche, menstrual history, or lifetime smoking. They were, however, less likely to have been pregnant (OR 0.14, 95% CI 0.03 to 0.71) or to have had children (OR 0.13, 95% CI 0.03 to 0.67). More pregnancies had ended in spontaneous abortion (28% v 8%) but the proportion of women undergoing spontaneous abortion was similar in cases and controls (OR 2.13, 95% CI 0.47 to 9.3).
CONCLUSIONS: This study does not support the hypothesis that use of the oral contraceptive pill is causally associated with the development of pulmonary lymphangioleiomyomatosis. Sex hormones may be involved, however, since patients were less likely to have been pregnant or to have had children, and tended to have had more spontaneous abortions and an increased incidence of fibroids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7940433      PMCID: PMC475191          DOI: 10.1136/thx.49.9.910

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Lymphangioleiomyomatosis. Clinical course in 32 patients.

Authors:  J R Taylor; J Ryu; T V Colby; T A Raffin
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

2.  Pulmonary lymphangiomyomatosis. A review.

Authors:  B Corrin; A A Liebow; P J Friedman
Journal:  Am J Pathol       Date:  1975-05       Impact factor: 4.307

3.  Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations.

Authors:  C B Carrington; D W Cugell; E A Gaensler; A Marks; R A Redding; J T Schaaf; A Tomasian
Journal:  Am Rev Respir Dis       Date:  1977-12

4.  Pulmonary lymphangiomyomatosis.

Authors:  E F Silverstein; K Ellis; M Wolff; A Jaretzki
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1974-04

5.  Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizing leiomyoma.

Authors:  A S Banner; C B Carrington; W B Emory; F Kittle; G Leonard; J Ringus; P Taylor; W W Addington
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

6.  Pulmonary lymphangiomyomatosis responsive to progesterone.

Authors:  K S McCarty; J A Mossler; R McLelland; H O Sieker
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

7.  Pulmonary lymphangiomyomatosis.

Authors:  R L Shuman; R Engelman; C F Kittle
Journal:  Ann Thorac Surg       Date:  1979-01       Impact factor: 4.330

Review 8.  Pulmonary lymphangioleiomyomatosis in postmenopausal women: report of two cases and review of the literature.

Authors:  S Baldi; M Papotti; M L Valente; M Rapellino; E Scappaticci; B Corrin
Journal:  Eur Respir J       Date:  1994-05       Impact factor: 16.671

9.  Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis.

Authors:  M H Colley; E Geppert; W A Franklin
Journal:  Am J Surg Pathol       Date:  1989-09       Impact factor: 6.394

10.  Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis.

Authors:  G A Rossi; B Balbi; S Oddera; S Lantero; C Ravazzoni
Journal:  Am Rev Respir Dis       Date:  1991-01
View more
  12 in total

Review 1.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.

Authors:  Hen Prizant; Aritro Sen; Allison Light; Sung-Nam Cho; Francesco J DeMayo; John P Lydon; Stephen R Hammes
Journal:  Mol Endocrinol       Date:  2013-07-02

3.  Clinical experience of lymphangioleiomyomatosis in the UK.

Authors:  S R Johnson; A E Tattersfield
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

4.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

5.  Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Authors:  Sergio Harari; Roberto Cassandro; Iacopo Chiodini; Jacopo Chiodini; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2007-12-10       Impact factor: 9.410

Review 6.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

7.  Lymphangioleiomyomatosis: a case-control study of perinatal and early life events.

Authors:  C I Whale; S R Johnson; K G Phillips; S A Newton; S A Lewis; A E Tattersfield
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

Review 8.  Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Stephen R Hammes; Vera P Krymskaya
Journal:  Horm Cancer       Date:  2012-11-27       Impact factor: 3.869

9.  Primary abdominal lymphangioleiomyomatosis: report of a case.

Authors:  Yuan Ding; Sheng Yan; Yang Tian; Zhiwei Li; Jun Pan; Qiyi Zhang; Yan Wang; Shusen Zheng
Journal:  World J Surg Oncol       Date:  2015-03-05       Impact factor: 2.754

10.  Association of retroperitoneal lymphangioleiomyomatosis with endosalpingiosis: a case report.

Authors:  José Manuel Lorente Herce; Virgilio Ruiz Luque; José Aguilar Luque; Pablo Martínez García; Daniel Díaz Gómez
Journal:  Cases J       Date:  2009-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.